Literature DB >> 6402781

Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex.

K M Brinkhous, M S Read, W A Fricke, R H Wagner.   

Abstract

Botrocetin, originally called venom coagglutinin, is a Bothrops factor that causes aggregation of blood platelets in the presence of the von Willebrand component of the factor VIII macromolecular complex. The complex consists of a series of multimers with a molecular weight of about 1-20 x 10(6). Ristocetin, another agent that causes platelet aggregation dependent on von Willebrand factor, reacts with only the higher molecular weight multimers. We report on the reactivity of botrocetin in relation to the multimeric structure of the factor VIII complex. Several plasmas or plasma fractions with abnormal distribution of the multimeric sizes were examined, including variant von Willebrand disease type IIA with lack of the higher molecular weight forms, commercial antihemophilic factor concentrates with a preponderance of lower molecular weight forms, cryoprecipitate-free plasma containing mainly the smaller multimers, and a chromatographic fraction of plasma containing only the highest molecular weight polymers. Factor VIII-related antigen content was adjusted to 25-100%. All of the preparations lacking the high molecular weight forms caused prompt platelet aggregation with botrocetin, but none of them caused aggregation in the ristocetin test made isochronal with the botrocetin test. The very high molecular weight polymers were equally effective with botrocetin and ristocetin. These findings indicate that the Bothrops factor is reactive with a broad spectrum of high to low molecular weight forms of the factor VIII complex, suggesting that bioassays of von Willebrand factor with botrocetin should correlate better with immunoassays for factor VIII-related antigen and could reflect better the full platelet-aggregating function of the complex than do ristocetin determinations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402781      PMCID: PMC393618          DOI: 10.1073/pnas.80.5.1463

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.

Authors:  J P Allain; H A Cooper; R H Wagner; K M Brinkhous
Journal:  J Lab Clin Med       Date:  1975-02

2.  Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying, freezing, or lyophilization: new stable platelet preparations for von Willebrand factor assays.

Authors:  K M Brinkhous; M S Read
Journal:  Thromb Res       Date:  1978-10       Impact factor: 3.944

3.  Comparison of factor VIII-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate.

Authors:  M Weinstein; D Deykin
Journal:  Blood       Date:  1979-06       Impact factor: 22.113

4.  Plasma levels of platelet aggregating factor/vom Willebrand factor in various species.

Authors:  K M Brinkhous; B D Thomas; S A Ibrahim; M S Read
Journal:  Thromb Res       Date:  1977-09       Impact factor: 3.944

5.  Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor.

Authors:  M S Read; R W Shermer; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

6.  Use of venom coagglutinin and lyophilized platelets in testing for platelet-aggregating von Willebrand factor.

Authors:  K M Brinkhous; M S Read
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

7.  Heterogeneity of human factor VIII. II. Characterization of forms of factor VIII binding to platelets in the presence of ristocetin.

Authors:  M H Doucet-de Bruïne; J J Sixma; J Over; N H Beeser-Visser
Journal:  J Lab Clin Med       Date:  1978-07

8.  Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.

Authors:  P M Blatt; K M Brinkhous; H R Culp; J S Krauss; H R Roberts
Journal:  JAMA       Date:  1976-12-13       Impact factor: 56.272

9.  Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.

Authors:  D Meyer; B Obert; G Pietu; J M Lavergne; T S Zimmerman
Journal:  J Lab Clin Med       Date:  1980-04

10.  Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.

Authors:  J Over; B N Bouma; J A van Mourik; J J Sixma; R Vlooswijk; I Bakker-Woudenberg
Journal:  J Lab Clin Med       Date:  1978-01
View more
  8 in total

1.  Isolation of a venom factor devoid of proteolytic activity from Taiwan habu (Trimeresurus mucrosquamatus): N-terminal sequence homology and no functional similarity to factors IX/X-binding proteins and botrocetin.

Authors:  S H Chiou; K F Huang; L P Chow; A Tsugita; S H Wu
Journal:  J Protein Chem       Date:  1996-10

2.  Primary structure of two-chain botrocetin, a von Willebrand factor modulator purified from the venom of Bothrops jararaca.

Authors:  Y Usami; Y Fujimura; M Suzuki; Y Ozeki; K Nishio; H Fukui; K Titani
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

3.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

4.  O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b.

Authors:  J A Carew; S M Quinn; J H Stoddart; D C Lynch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

5.  Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor.

Authors:  D A Bellinger; T C Nichols; M S Read; R L Reddick; M A Lamb; K M Brinkhous; B L Evatt; T R Griggs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Snake Venom: Any Clue for Antibiotics and CAM?

Authors:  Deivy Clementino de Lima; Paula Alvarez Abreu; Cícero Carlos de Freitas; Dilvani Oliveira Santos; Rodrigo Oliveira Borges; Tereza Cristina Dos Santos; Lúcio Mendes Cabral; Carlos R Rodrigues; Helena Carla Castro
Journal:  Evid Based Complement Alternat Med       Date:  2005-03       Impact factor: 2.629

7.  Functional display of platelet-binding VWF fragments on filamentous bacteriophage.

Authors:  Andrew Yee; Fen-Lai Tan; David Ginsburg
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

Review 8.  Inflammation Induced by Platelet-Activating Viperid Snake Venoms: Perspectives on Thromboinflammation.

Authors:  Catarina Teixeira; Cristina Maria Fernandes; Elbio Leiguez; Ana Marisa Chudzinski-Tavassi
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.